Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
US Department of Justice
Fish and Richardson
Cantor Fitzgerald
Daiichi Sankyo
Mallinckrodt
QuintilesIMS
Accenture

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,039,479

« Back to Dashboard

Which drugs does patent 8,039,479 protect, and when does it expire?


Patent 8,039,479 protects ZYKADIA and is included in one NDA.

This patent has ninety patent family members in forty-three countries.

Summary for Patent: 8,039,479

Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Inventor(s): Michellys; Pierre-Yves (San Marcos, CA), Pei; Wei (San Diego, CA), Marsilje; Thomas H. (San Diego, CA), Chen; Bei (San Diego, CA), Uno; Tetsuo (San Diego, CA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:11/943,436
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,039,479

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,957,081Compounds and compositions as protein kinase inhibitors► Subscribe
8,372,858Compounds and compositions as protein kinase inhibitors► Subscribe
8,399,450Compounds and compositions as protein kinase inhibitors► Subscribe
8,440,6812-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors► Subscribe
8,377,921Compounds and compositions as protein kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,039,479

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
San MarinoP200900058► Subscribe
San MarinoAP200900058► Subscribe
San Marino201000108► Subscribe
Slovenia2091918► Subscribe
Serbia53588► Subscribe
Portugal2091918► Subscribe
Peru14472008► Subscribe
Peru08142012► Subscribe
New Zealand590601► Subscribe
New Zealand577197► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Army
Medtronic
Farmers Insurance
Mallinckrodt
Teva
Express Scripts
Accenture
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot